Princess Margaret Phase I Consorium (PMP1C)

玛格丽特公主一期联盟 (PMP1C)

• 批准号: 9762723
• 负责人: Steven Grant
• 金额: $ 34.14万
• 依托单位: UNIVERSITY HEALTH NETWORK
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2020-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9762723
• 关键词: Address; Adopted; Amendment; American; Antineoplastic Agents; Award; Biological; British Columbia; Canada; Cancer Center; Cause of Death; Clinic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical trial protocol document; Collaborations; Data; Disease; Drug Industry; Drug resistance; Early Therapeutic-Clinical Trials Network; Enrollment; Evaluation; Florida; Fostering; Funding Opportunities; Genotype; Geographic state; Geography; Goals; Healthcare; Industry; Institutes; Investigational Therapies; Laboratories; Lead; Leadership; Malignant Neoplasms; Mentorship; Methodology; Molecular; NCI Center for Cancer Research; National Cancer Institute of Canada Clinical Trials Group; Ontario; Outcome; Pathologist; Patients; Pharmacology; Phase; Positioning Attribute; Prediction of Response to Therapy; Principal Investigator; Process; Province; Research; Research Institute; Research Personnel; Research Support; Resistance; Resources; Safety; Science; Source; Specimen; Technology; Training; Training and Education; Translating; Translational Research; Work; anticancer treatment; base; biomarker development; career development; clinical care; college; design; drug development; drug sensitivity; early phase trial; exome; immune function; innovation; interdisciplinary approach; member; next generation sequencing; novel; novel anticancer drug; quantitative imaging; response; targeted sequencing; tumor; whole genome

The Princess Margaret Phase I Consortium (PMPIC), led by Dr. Lillian Siu, consists of the Princess Margaret Cancer Centre (PM) as its Lead Academic Organization (LAO) and three Affiliated Organizations (AO): Moffitt Cancer Center (MCC), Juravinski Cancer Centre (JCC) and British Columbia Cancer Agency (BCCA). The Specific Aims of PMPIC resonate closely with the goals of the ET-CTN: 1)To conduct innovative, coordinated, efficient, regulatory-compliant and high impact early phase clinical trials in experimental therapeutics, which are designed to address important questions that do not duplicate research supported by the pharmaceutical industry or other sources; 2) To adopt a team science interdisciplinary approach with internal and external collaborations to enhance the optimal evaluation of novel anticancer agents alone or in combination; 3) To accelerate biomarker development and correlative sciences research through comprehensive molecular characterization of tumors obtained from patients enrolled on ET-CTN trials to elucidate mechanism of action, as well as predictors of therapeutic response and/or resistance; and 4) To emphasize training and education to foster career development of junior investigators. PMPIC is committed to actively lead ET-CTN early phase trials as well as to contribute as a meaningful partner to ET-CTN trials led by other Consortia. With a strong Leadership that is supported by the Steering Committee, Translational Research, Clinical Research and Operational Cores, PMPIC embraces a team science approach to conduct the most relevant early phase clinical trials of novel agents alone or in combination. All patients enrolled by the PMPIC will undergo comprehensive molecular characterization using advanced genotyping or targeted sequencing approaches to help identify drivers of drug sensitivity or resistance. This data, along with pharmacological, immune function, and quantitative imaging data, will enable the most optimal biological correlation with clinical outcome. Leveraging resources from other sources including institutional support, the PMP1C will further advances whole exome/whole genome next generation sequencing technologies within the timeframe of this award in the next 5 years.

由莉莲·苏（Lillian Siu）博士领导的玛格丽特公主玛格丽特（PMPIC）由公主组成 玛格丽特癌症中心（PM）作为其主要学术组织（LAO）和三个附属组织 （AO）：Moffitt癌症中心（MCC），Juravinski癌症中心（JCC）和不列颠哥伦比亚省癌症局 （BCCA）。 PMPIC的具体目的与ET-CTN的目标紧密共鸣：1） 创新，协调，高效，符合法规符合性和高影响力早期临床试验 实验治疗剂，旨在解决不复制研究的重要问题 由制药行业或其他来源的支持； 2）采用团队科学跨学科 与内部和外部协作的方法，以增强对新型抗癌的最佳评估 单独或组合代理； 3）加速生物标志物发展和相关科学研究 通过从参加ET-CTN的患者获得的肿瘤的全面分子表征 阐明作用机理的试验以及治疗反应和/或抗性的预测因素；和 4）强调培训和教育以促进初级研究人员的职业发展。 PMPIC致力于积极领导ET-CTN早期试验，并作为有意义的 由其他财团领导的ET-CTN试验的合作伙伴。在转向的支持下，有强大的领导 PMPIC委员会，翻译研究，临床研究和运营核心 科学方法是单独或在 组合。所有由PMPIC招募的患者都将接受全面的分子表征 使用先进的基因分型或靶向测序方法来帮助识别药物敏感性的驱动力或 反抗。这些数据以及药理，免疫功能和定量成像数据将 使最佳的生物学与临床结局具有最佳的生物学相关性。利用其他资源 包括机构支持在内的来源，PMP1C将进一步发展整个外显/整个基因组接下来 在未来5年内，该奖项的时间范围内的生成测序技术。